Archive

Neovasc Provides a General Update, Announces Filing of Annual Report on Form 20-F and Sets First Quarter 2018 Financial Results Conference Call and Webcast

Posted on April 30, 2018
in
by

NASDAQ, TSX: NVCN VANCOUVER, April 30, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today provided a general corporate update, concurrent with filing its Annual Report on Form 20-F,...

Read More

Neovasc Announces Receipt of US$7.1 Million from Exercise of Series C Warrants

Posted on April 11, 2018
in
by

NASDAQ, TSX: NVCN VANCOUVER, April 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and the Neovasc Reducer™ (the "Reducer") therapy for Refractory Angina, today announced that it has...

Read More

Neovasc Announces Results for the Fourth Quarter and Fiscal Year 2017

Posted on March 28, 2018
in
by

NASDAQ, TSX: NVCN VANCOUVER, March 28, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and the Reducer therapy for Refractory Angina, today announced financial results for the fourth quarter...

Read More

Neovasc Announces Year End 2017 Financial Results Conference Call and Webcast

Posted on March 21, 2018
in
by

NASDAQ, TSX: NVCN VANCOUVER, March 21, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will report financial results for the year ended December 31, 2017...

Read More

Neovasc to Present at LEERINK Partners 7th Annual Global Healthcare Conference

Posted on February 12, 2018
in
by

NASDAQ, TSX: NVCN VANCOUVER, Feb. 12, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that Fred Colen, President and Chief Executive Officer of Neovasc, is scheduled to present at the LEERINK Partners 7th Annual Global Healthcare Conference on Wednesday, February 14th...

Read More

Neovasc Announces Receipt of German NUB Status 1 Designation for Neovasc Reducer™ Procedure for Treatment of Refractory Angina

Posted on February 1, 2018
in
by

Participating Hospitals in Germany Now Eligible to Negotiate Reimbursement for Reducer Procedure NASDAQ, TSX: NVCN VANCOUVER, Feb. 1, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies, today announced that the "Institut...

Read More

Fred Colen Appointed Chief Executive Officer of Neovasc Inc.

Posted on January 22, 2018
in
by

Recognized Multinational Senior Executive Poised to Drive Commercialization and Clinical Advances NASDAQ, TSX: NVCN VANCOUVER, Jan. 22, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (Nasdaq, TSX: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the "Board") has...

Read More